4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,574,607 | -29.6% | 437,911 | 0.0% | 1.23% | -17.0% |
| Q2 2023 | $7,913,052 | +5.1% | 437,911 | 0.0% | 1.48% | +1.0% |
| Q1 2023 | $7,527,690 | -22.6% | 437,911 | 0.0% | 1.46% | -34.7% |
| Q4 2022 | $9,726,003 | +228.4% | 437,911 | +18.9% | 2.24% | +230.0% |
| Q3 2022 | $2,962,000 | +62.3% | 368,411 | +40.9% | 0.68% | +60.0% |
| Q2 2022 | $1,825,000 | -8.6% | 261,423 | +97.9% | 0.42% | -13.6% |
| Q1 2022 | $1,997,000 | -31.1% | 132,090 | 0.0% | 0.49% | -30.3% |
| Q4 2021 | $2,898,000 | +88.2% | 132,090 | +131.4% | 0.71% | +44.7% |
| Q3 2021 | $1,540,000 | +12.0% | 57,090 | 0.0% | 0.49% | +3.4% |
| Q2 2021 | $1,375,000 | -36.6% | 57,090 | +14.2% | 0.47% | -44.5% |
| Q1 2021 | $2,169,000 | +4.6% | 50,000 | 0.0% | 0.85% | -35.8% |
| Q4 2020 | $2,073,000 | – | 50,000 | – | 1.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |